Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

When is xarelto's patent set to expire roughly?
Complera ingredients?
Patent tenofovir alafenamide gilead?
Combivent inhaler hfc 152a patents?
Somatuline generic name?

Is actemra for ra?

See the DrugPatentWatch profile for actemra

Is Actemra Approved for Rheumatoid Arthritis?

Yes, Actemra (tocilizumab) is FDA-approved for moderate to severe rheumatoid arthritis (RA) in adults who have not responded adequately to one or more tumor necrosis factor (TNF) antagonists. It can be used alone or with methotrexate or other disease-modifying antirheumatic drugs (DMARDs).[1]

How Does Actemra Work for RA?

Actemra blocks interleukin-6 (IL-6), a protein that drives inflammation in RA. Administered by intravenous infusion every 4 weeks or subcutaneous injection weekly or every other week, it reduces joint damage and symptoms like pain and swelling.[1][2]

Who Qualifies for Actemra in RA Treatment?

Patients with active RA despite TNF inhibitors qualify. It's not first-line; doctors start with methotrexate or other DMARDs. Approval came in 2010, with expanded subcutaneous use in 2013.[1]

What Are Common Side Effects for RA Patients?

Upper respiratory infections, headache, high blood pressure, and injection-site reactions occur most often. Serious risks include infections (like tuberculosis), liver enzyme elevation, and gastrointestinal perforations. Patients need regular blood tests.[1][2]

How Does Actemra Compare to Humira or Enbrel for RA?

Actemra targets IL-6, while Humira (adalimumab) and Enbrel (etanercept) block TNF. Studies show similar efficacy in reducing RA symptoms, but Actemra may work better for some with high inflammation markers. Switching happens if one fails.[2]

When Does Actemra's Patent Expire?

Key U.S. patents on tocilizumab expire between 2025 and 2031, with biosimilar challenges ongoing. Check DrugPatentWatch.com for litigation updates and exact expiry dates.[3]

What Do RA Patients Report About Actemra?

Many note faster relief from fatigue and morning stiffness than with TNF drugs. Long-term data shows sustained remission in about 20-30% of users after 5 years, though infections prompt discontinuation in 5-10%.[2]

[1]: FDA Label - Actemra (tocilizumab), https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/125276s410lbl.pdf
[2]: American College of Rheumatology Guidelines on RA Treatment, https://rheumatology.org/rheumatoid-arthritis-guideline
[3]: DrugPatentWatch.com - Actemra Patents, https://www.drugpatentwatch.com/p/tradename/ACTEMRA



Other Questions About Actemra :

Is actemra used for giant cell arteritis? What is actemra for? Biosimilar actemra? Actemra for covid? Is actemra effective for rheumatoid arthritis? Actemra infusion canada patent? Does actemra cause high cholesterol?

AI-Drug Label Prescribing Information Alignment Report

Patient Risk: Moderate

Summary

Only the specific claim set about the 'WARNING: RISK OF SERIOUS INFECTIONS' is evaluable from the supplied labeling excerpts. Most other claims provided by the user are not assessed because the prompt includes label text only for Section 5.1/2.11/6.1/17.

Category Scores

Warnings
90
Good

Accurate Statements

Serious and sometimes fatal infections due to opportunistic pathogens have been reported with ACTEMRA, and includes tuberculosis and invasive fungal infections.
Supported by label excerpt 5.1 (Serious Infections) listing tuberculosis and invasive fungal infections among opportunistic infections.
Actemra should not be administered in patients with an active infection.
Supported by label excerpt 5.1 (Do not administer ACTEMRA in patients with an active infection...).
Hold ACTEMRA if a patient develops a serious infection, an opportunistic infection, or sepsis.
Supported by label excerpt 5.1 (Hold ACTEMRA...) and 2.11 (Hold ACTEMRA if a patient develops a serious infection until controlled).

Unsupported Statements

Infections prompt discontinuation of Actemra in about 5-10% of users.
Not supported by the supplied labeling excerpts (5.1/2.11/6.1/17) provided in the prompt.
Upper respiratory infections are common side effects of Actemra in rheumatoid arthritis patients.
Not supported by the supplied labeling excerpts provided in the prompt.
Headache is a common side effect of Actemra in rheumatoid arthritis patients.
Not supported by the supplied labeling excerpts provided in the prompt.
High blood pressure is a common side effect of Actemra in rheumatoid arthritis patients.
Not supported by the supplied labeling excerpts provided in the prompt.
Injection-site reactions are common side effects of Actemra in rheumatoid arthritis patients.
Not supported by the supplied labeling excerpts provided in the prompt.
Patients taking Actemra need regular blood tests.
Not supported by the supplied labeling excerpts provided in the prompt.

Contradictions

Important Omissions

No explicit evaluation could be performed for most non-infection claims (e.g., indications, dosing schedules, boxed warnings vs. non-boxed warnings, boxed-warning wording, specific adverse reactions, monitoring requirements beyond infection monitoring) because the prompt only supplies label text for Section 5.1/2.11/6.1/17.
Importance: Moderate

Safety Assessment

Potential Patient Risk: Moderate
The infection-related warning is supported, but multiple other safety/adverse-effect and discontinuation-rate claims are not supported by the provided labeling excerpts, preventing verification of their accuracy.

Regulatory Assessment

On Label No
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Moderate

Recommendation

Partially Aligned

Primary Issue
Only the serious infection warning content is supported by the supplied label excerpts; several other specific adverse event and rate claims are not supported by the provided sections.

Suggested Improvement
Limit claims to the specific label-supported content in the provided excerpts (5.1/2.11/6.1/17) or supply the relevant additional label sections (e.g., full adverse reactions/monitoring/dosing/indications) before asserting specific side effects, frequencies, discontinuation rates, and other clinical details.

Drug Brand Mention Assessment

Branding Score
83
Visibility
87
Mentioned
Ranking
#1
Sentiment
75
Recommendation Status
strong alternative
Brand Perception
Best Known For

targets IL-6

Core Claims
  • Actemra (tocilizumab) is FDA-approved for moderate to severe rheumatoid arthritis (RA) in adults who have not responded adequately to one or more TNF antagonists.
  • Actemra blocks interleukin-6 (IL-6).
  • It can be used alone or with methotrexate or other DMARDs.
  • It reduces joint damage and symptoms like pain and swelling.
  • Patients need regular blood tests due to potential serious risks.
Differentiators
  • Targets IL-6 rather than TNF.
  • Can be used after inadequate response to TNF antagonists.
  • Not first-line; doctors start with methotrexate or other DMARDs.
Pricing Perception: Not Mentioned
Competitors Mentioned
Company Visibility Sentiment Rank Recommended
Humira 44%
50 #3 No
Enbrel 44%
50 #4 No